Navigation Links
InfoGroup Founder and Board Member Criticizes Adoption of Poison Pill
Date:5/18/2009

Board Should Pursue Strategic Alternatives Rather than Seek to Entrench Itself

OMAHA, Neb., May 18 /PRNewswire/ -- Vinod Gupta, the founder, member of the board of directors and holder of approximately 39% of the outstanding stock of InfoGroup (Nasdaq: IUSA) announced today that he strongly disagreed with the Company's recent decision to adopt a poison pill and believes that the Company must explore strategic alternatives.

"I believe that the Board of Directors' adoption of a 'poison pill' demonstrates that many of the directors are willing to entrench themselves at the expense of the Company's stockholders," said Mr. Gupta. "Unfortunately, this conduct is consistent with past Board actions. When I entered into a settlement agreement with the Company in 2008, the Board insisted that I vote all my shares in favor of the Board's nominees for director rather than proportionately with the shares of the Company's unaffiliated stockholders, as I had strongly demanded. The Board simply wanted to control my votes (approximately 39% of the Company's voting stock) to assure that they could keep their board seats rather than give the stockholders, to whom they should owe their allegiance, a meaningful say in the election of directors," Mr. Gupta stated.

"I regret that some members of this Board, who do not own a meaningful amount of stock in the Company like I do, seem much more interested in assuring that they retain their directorships than in doing what is best for the stockholders of the Company. I sincerely hope that all stockholders, as well as Risk Metrics, let these members of the Board know their displeasure with the Board's decision to adopt a rights plan," Mr. Gupta continued.

"It is bad enough that a majority of the Board would take this action against the best interests of all of the stockhold
'/>"/>

SOURCE Vinod Gupta
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
2. Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a Clean SCHIP Six-Month Extension
3. Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer
4. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
5. Susan G. Komen for the Cure Founder Sworn in as Chief of Protocol
6. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
7. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
8. Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show
9. Lenny Dykstra, Founder & President of The Players Club, to Keynote the 2008 Financial Communications Forum
10. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
11. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... By Amy Norton ... -- Yoga has long been believed to improve overall health, ... may also help the heart, a new review finds. ... exercise such as brisk walking, said lead researcher Paula Chu, ... Boston. The review, of 37 clinical trials, found that ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... , Jan. 28 Code Hennessy & Simmons ... portfolio investment of CHS Private Equity V LP and Linden ... private equity firm.   , Suture Express is a distributor ... products.  Suture Express offers over 1,600 acute care hospitals and ...
... used with chemo for HER2 malignancies, researchers report , ... patients with HER2-positive tumors benefit from receiving the targeted ... "It,s in a European journal [The Lancet], but it,s ... begun to do," said Dr. Jay Brooks, chairman of ...
... , DENVER , Jan. 28 ... it has entered into an agreement to acquire Highlands Ranch ... the Denver suburb of Highlands Ranch . ... satisfaction of other requirements as detailed in the agreement.   ...
... Jan. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... Each of the dividends will be $0.50 per share. The first ... stockholders who own shares of PDL on March 15, 2010 , the ... 2010 to all stockholders who own shares of PDL on September ...
... , DETROIT , Jan. 28 Caraco Pharmaceutical ... $52.0 million and $178.4 million for the ... to $55.7 million and $286.2 million , respectively, ... the third quarter and first nine months of Fiscal 2010, in ...
... trigger a medical evaluation for ovarian cancer does not appear ... in diagnosis in only 1 out of 100 women in ... published online January 28 in the Journal of the ... Hutchinson Cancer Research Center in Seattle assessed the predictive value ...
Cached Medicine News:Health News:Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc. 2Health News:Code Hennessy & Simmons LLC Announces Sale of Suture Express, Inc. 3Health News:Herceptin Again Proves Mettle Against Breast Cancer 2Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 2Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 3Health News:Grubb & Ellis Healthcare REIT II Enters Agreement to Acquire Highlands Ranch Medical Pavilion Near Denver 4Health News:PDL BioPharma Announces Two $0.50 Dividends in 2010 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 8Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010 9Health News:Symptoms have little value for early detection of ovarian cancer 2
(Date:12/17/2014)... STUTTGART, Germany , December 17, 2014 ... high level of expenditure on research and development ... ZEISS increased its revenue by two percent to EUR 4.287 ... Earnings (EBIT) grew by 14 percent to EUR 360 million. ... Group," said Dr. Michael Kaschke , President and CEO ...
(Date:12/17/2014)... Dec. 17, 2014  Beamz Interactive, Inc. (OTCQB: ... products, today announced that it has signed an ... and supplier of innovative prosthetic, orthotic and assistive ... of the agreement, RSL Steeper will promote and ... configured for use within UK residential care facilities ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... Eisai Corporation of North,America announced today that ... the company,s oncology pipeline, product portfolio and,preclinical oncology ... Annual Meeting of the American Society of Clinical ... to June 3, 2008., A wide variety ...
... FRANCISCO, May 15 Medivation, Inc.,(Nasdaq: MDVN ) ... clinical,trial of its novel androgen receptor antagonist, MDV3100, will ... Society of Clinical Oncology,(ASCO) Annual Meeting in Chicago., ... Prostate Cancer Session date and time: Monday, June ...
Cached Medicine Technology:Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
Ademtechs Magnetic Beads are produced by encapsulation of a magnetic oil (patented technology). The magnetic content, uniform particle size, mono-dispersion properties, and the high surface area allo...
For general purposes...
... BcMag Streptavidin magnetic beads are ... of biotinylated molecules such as ... from cell lysates or hybridization ... highly dispersed, it can also ...
Medicine Products: